Optometry and Vision Science
July 1, 1968
Meredith W. Morgan
143 citations
Changes of spatial distortion threshold in response to the hallucinogen, psilocybin, were measured. A marked loss of compensation for optically induced distortions at drug peak was found. Compensation returned as the drug course elapsed.
Journal of AOAC International
1968
Robert J. Martin, Thomas G. Alexander
6 citations
Abstract Various ultraviolet, infrared, and TLC procedures are described for the separation and identification of hallucinogenic drugs. Specific methods for LSD, DMT, and psilocybin are also presented, along with general background information for the hallucinogenic drugs.
Science
November 3, 1967
Solomon H. Snyder, Louis A. Faillace, Leo E. Hollister
146 citations
We have assessed the effects in normal control volunteers of 2,5-dimethoxy-4-methyl-amphetamine, the chemical present in the hallucinogenic drug STP, in two independent trials. In low doses, this compound produces a mild euphoria. Doses greater than 3 milligrams may cause pronounced hallucinogenic effects lasting about 8 hours and similar to those produced by hallucinogenic doses of lysergic...
Psychiatry and Clinical Neurosciences
June 1, 1967
Y Shimazono, Katsumi Ando, Takashi Tanaka et al.
4 citations
S ummary In 45 normal subjects changes in the horizontal eye movements following the administration of psychotropic drugs have been studied. 1. Following the administration of amobarbital (250 mg, i.v.) and chlorpromazine (1.0mg/kg, i.m.), rapid eye movements (R) decreased gradually until they disappeared altogether. 2. LSD 25 (0.5 or 1.0γ/kg, i.m.) produced increase of R in 80% and markedly...
Archives of General Psychiatry
May 1, 1967
Malcolm B. Bowers
22 citations
THE PUBLIC has become aware of the increasing use of the major psychedelic substances (lysergic acid diethylamide [LSD], peyote, psilocybin, morning glory seeds) by certain individuals outside the contexts of supervised therapy and research.1,2Several excellent clinical studies have firmly documented the hazards of this Practice.4,5At a time when the scientific community has been gathering...
Archives of General Psychiatry
November 1, 1966
Max Fink
40 citations
THE INCREASED abuse of lysergic acid diethylamide (LSD) has aroused popular concern for its complications and has led the leading pharmaceutical manufacturer to withdraw its supplies from investigational use. Recent reports, especially those in the lay press, give the impression of an increasing incidence of persistent psychoses, associating the observations with the illicit use of LSD.1,2 The...
Archives of Internal Medicine
September 1, 1966
Erwin Di Cyan
2 citations
The final paragraph of the 20-page chapter "A Brief Review" (and it is, by-and-large, a good review) reads: "We feel that detailed first-hand accounts of experiencesas they occurred(typescripts of tape recordings) by subjects, screened for stability, in sensorilly controlled environments, will help to resolve the question of whether the hallucinogenic experience should be an available adjunct...
JAMA
July 12, 1965
Donald E. Widmann
37 citations
The medical community was alarmed recently by the uncontrolled and somewhat-promiscuous use of "hallucinogens" in one of our major cities. The lay press contained many accounts suggesting the various hallucinogenic properties, but emphasized that the drugs seemed to provide the user with something of a mystic experience— what has been called "instant Zen." InThe Beyond Withinthe author places...
JAMA
March 7, 1964
Jonathan Cole, Martin M. Katz
16 citations
FOR MANY YEARS several pharmacologically similar drugs—lysergic acid diethylamide (LSD-25), psilocybin, and mescaline, among others—have been of special scientific interest. In volunteer subjects, they have been known to produce a variety of intense and unusual psychic effects. These include bizarre visual phenomena, ranging from a heightening of the apparent brightness or beauty of colored...
JAMA
March 7, 1964
Roy R. Grinker
16 citations
For several years, quietly and without publicity, several scientists have been studying the behavioral pharmacology of lysergic acid diethylamide (LSD-25), and lately psilocybin, on experimental animals and human subjects. The psychotic effects of these drugs have some but not complete similarity to the schizophrenic psychoses, which has resulted in their classification as psychomimetics. Yet...